Paper Details

  1. Home
  2. Paper Details

Fast effectiveness of a solubilized low-dose budesonide nasal spray in allergic rhinitis.

Author: GoesslAndreas, LemellPatrick, NakowitschSabine, Prieschl-GrassauerEva, SavliMarkus, SchmutzRené, Unger-ManhartNicole, ZieglmayerPetra, ZieglmayerRené

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Equivalence TrialA clinical trial designed to show that a new treatment is equivalent in efficacy/safety to an existing treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Budesolv 10, a novel aqueous formulation of budesonide, was non-inferior to Rhinocort® Aqua 64 (RA) in treating grass pollen allergic rhinoconjunctivitis. Budesolv 10 showed a significant reduction in nasal and respiratory symptoms starting 90 minutes after application, demonstrating an early onset of efficacy. Budesolv 10 may be an effective acute treatment for allergic rhinitis and AR comorbidities like mild asthma and conjunctivitis.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Budesonide, a poorly water-soluble corticosteroid, is currently marketed as a suspension. Budesolv is a novel aqueous formulation containing dissolved budesonide showing increased local availability in preclinical models. Budesolv contains ~85% less corticosteroid than the marketed compa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540702/

データ提供：米国国立医学図書館（NLM）

A Solubilized Low-Dose Budesonide Nasal Spray: A Game-Changer for Allergic Rhinitis

Allergic rhinitis, also known as hay fever, is a common condition that affects millions worldwide. It's like a pesky camel who keeps showing up at your door, uninvited, during allergy season. But don't worry! Researchers are constantly striving to find better ways to manage this condition. This study delves into the effectiveness of a novel budesonide nasal spray called Budesolv, which boasts a quicker onset of action compared to existing treatments. It's like having a camel trainer who can tame the allergy beast faster and more effectively than before!

Budesolv: A Quick and Effective Treatment

The study found that Budesolv was equally effective as the current standard treatment, Rhinocort® Aqua 64, in controlling symptoms. However, Budesolv used significantly less budesonide, demonstrating a more efficient approach to managing allergy symptoms. The researchers also observed that Budesolv provided relief much faster than the standard treatment, with significant symptom reduction noted within 90 minutes of application. This early onset of action is a major benefit for patients who want quick relief from the misery of allergic rhinitis.

Managing Allergic Rhinitis: A New Approach

This research provides valuable insights into the potential of Budesolv as a new treatment option for allergic rhinitis. Its quick effectiveness and lower dose make it a promising alternative for patients seeking faster symptom relief. Now, we can envision a future where allergies are no longer a major obstacle to enjoying life.

Dr.Camel's Conclusion

Budesolv is a promising treatment for allergic rhinitis, offering a faster onset of action and a lower dose than existing options. This research provides hope for patients seeking effective and efficient relief from allergy symptoms. With a quicker response, Budesolv might be the camel-riding solution to allergy woes!
Date :
  1. Date Completed 2021-11-02
  2. Date Revised 2021-11-02
Further Info :

Pubmed ID

32569395

DOI: Digital Object Identifier

PMC7540702

Related Literature

Article Analysis
・Effects of budesonide nasal spray
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.